Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Exelixis Q2 2026 results detail zanzalintinib pipeline progress, narrows guidanceAug 5Quarterly updateExelixisMerck & Co., Inc.
Sign inSign in